Literature DB >> 19106238

Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies.

Linda A J van Mierlo1, Mettina M G Koning, Kim van der Zander, Richard Draijer.   

Abstract

BACKGROUND: Dietary factors directly influence blood pressure (BP). The lactotripeptides (LTPs) IPP (isoleucine-proline-proline) and VPP (valine-proline-proline), formed by hydrolyzing dairy proteins, and potassium, a mineral mainly found in fruit, vegetables, and dairy products, are extensively studied for their BP-lowering effect. The efficacy of LTPs seems modest in whites compared with that in Asians.
OBJECTIVE: The objective was to study the effects of enzymatically produced LTPs alone or in combination with potassium on ambulatory BP in whites.
DESIGN: Two multicenter, placebo-controlled, randomized, crossover studies were conducted; each consisted of two 4-wk intervention periods separated by a 4-wk washout period. In study 1, 69 subjects received 200 g/d of a dairy drink with 5.8 mg IPP and 4.4 mg VPP or placebo. In study 2, 93 subjects received 100 g/d of a dairy drink with 2.7 mg IPP, 1.9 mg VPP, and 350 mg added K or placebo. The subjects were randomly assigned according to their daytime ambulatory BP.
RESULTS: Mean 24-h systolic and diastolic BP (baseline values-study 1: 137.1/81.6 mm Hg; study 2: 139.2/80.9 mm Hg) remained similar with no significant differences between treatments in either study (P > 0.10). Office BP decreased over the course of both studies (systolic BP > 5 mm Hg), but differences between interventions were not significant (P > 0.10). In both studies, nighttime BP dipped during all treatments (> or =15%) but was statistically more significant with placebo (P < 0.05). Sodium excretion increased significantly after consumption of LTPs and potassium compared with after placebo intervention (P = 0.01), but not after consumption of LTPs alone.
CONCLUSION: The data do not support a BP-lowering effect of LTPs in whites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19106238     DOI: 10.3945/ajcn.2008.26918

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  7 in total

1.  IPP-rich milk protein hydrolysate lowers blood pressure in subjects with stage 1 hypertension, a randomized controlled trial.

Authors:  Esther Boelsma; Joris Kloek
Journal:  Nutr J       Date:  2010-11-08       Impact factor: 3.271

2.  The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives.

Authors:  F Wilford Germino; Joel Neutel; Mako Nonaka; Sheldon S Hendler
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-03       Impact factor: 3.738

3.  Enhanced Lacto-Tri-Peptide Bio-Availability by Co-Ingestion of Macronutrients.

Authors:  Gabriella A M Ten Have; Pieter C van der Pijl; Arie K Kies; Nicolaas E P Deutz
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 4.  Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials.

Authors:  Ágnes A Fekete; D Ian Givens; Julie A Lovegrove
Journal:  Nutrients       Date:  2015-01-20       Impact factor: 5.717

Review 5.  Antihypertensive Peptides from Milk Proteins.

Authors:  Pauliina Jäkälä; Heikki Vapaatalo
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-19

Review 6.  Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system.

Authors:  Cuie Guang; Robert D Phillips; Bo Jiang; Franco Milani
Journal:  Arch Cardiovasc Dis       Date:  2012-06-15       Impact factor: 2.340

7.  Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials.

Authors:  Arrigo F G Cicero; Francois Aubin; Veronique Azais-Braesco; Claudio Borghi
Journal:  Am J Hypertens       Date:  2013-01-07       Impact factor: 2.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.